Extended-spectrum beta-lactamases: Their role in clinical microbiology laboratory, treatment and infection control Genişlemiş spektrumlu beta laktamazlar: Klinik mikrobiyoloji laboratuvari, tedavi ve enfeksiyon kontrolündeki rolleri


Dolapçi I.

Mikrobiyoloji Bulteni, cilt.39, sa.2, ss.229-240, 2005 (SCI-Expanded, Scopus, TRDizin) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 39 Sayı: 2
  • Basım Tarihi: 2005
  • Dergi Adı: Mikrobiyoloji Bulteni
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.229-240
  • Anahtar Kelimeler: Epidemiology, Extended-spectrum beta-lactamases, Identification methods
  • Ankara Üniversitesi Adresli: Evet

Özet

The major mechanism responsible for resistance to β-lactam antibiotics is the production of β-lactamases. These enzymes, which have the ability to inactivate extended-spectrum β-lactam antibiotics, like cefotaxime and ceftazidime are called as extended-spectrum β-lactamases (ESBL). The most important pathogen which produces β-lactamases among Gram positive bacteria is Staphylococcus aureus and the members of the Enterobacteriaceae family are the leading β-lactamase producing organisms among Gram negative bacteria. Although the β-lactamase inhibitors like clavulanic acid, sulbactam and tazobactam could block ESBL effects, ESBL's have still been considered as a threat since they are coded by plasmids and can easily be transmitted between species. Recently, more than 150 ESBLs have been identified. Numerous methods have been proposed for the detection of ESBLs in clinical isolates. Imipenem seems to be the most effective agent for the therapy and control of the spread of infections caused by ESBL-producing bacteria. In this review article, the roles of ESBL in clinical microbiology laboratory, treatment and infection control, have been discussed.